secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEKTAR THERAPEUTICS (NKTR)
CIK:        0000906709
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001213900-23-037687
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nektar Q1 2023 net loss $137M; regains rezpegaldesleukin rights from Lilly
--------------------------------------------------------------------------

- Net loss of $137.0M ($0.73/share) vs. $90.4M ($0.49) in Q1 2022.
- Non-GAAP net loss of $47.3M ($0.25/share) excluding $89.7M in impairment charges.
- Revenue $21.6M, down from $24.8M; R&D expense fell to $30.5M from $107.3M.
- Cash and investments $456.8M; expected to fund operations into mid-2026.
- Regained full rights to rezpegaldesleukin from Eli Lilly; plans Phase 2b atopic dermatitis study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/906709/000121390023037687/0001213900-23-037687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/906709/000121390023037687/ea178178-8k_nektar.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-037687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer